Hang Su

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

Yuankai Shi, Hang Su, Yongping Song et al. · The Lancet Haematology · 2019 · 249 citations

Life Sciences, Immunology, Oncology +7

Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making

Si-Ye Chen, Yong Yang, Shu‐Nan Qi et al. · Leukemia · 2020 · 131 citations · Full text

Medicine, Oncology, Cancer Immunology +13

Evaluation of sn-2 fatty acid composition in commercial infant formulas on the Chinese market: A comparative study based on fat source and stage

Cong Sun, Wei Wei, Hang Su et al. · Food Chemistry · 2017 · 114 citations

Agriculture, Food Science, Nutritional Sciences +17

Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Yuankai Shi, Jianqiu Wu, Zhen Wang et al. · Journal of Hematology & Oncology · 2021 · 63 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG

Shu‐Nan Qi, Yong Yang, Yu-Qin Song et al. · Blood Advances · 2020 · 57 citations · Full text

Medicine, Oncology, Cancer Immunology +12